Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Next Previous
Trial Profile

An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 06 Nov 2019 Results of pooled post-hoc analysis assesing overall survival by using data from three studies including this study released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
  • 06 Nov 2019 According to a Kiadis Pharma media release, new ATIR101 data will be discussed in an oral presentation exploring the effect of a single infusion of ATIR101 on survival outcomes in patients with blood cancer who underwent T-cell depleted haploidentical-hematopoietic stem cell transplantation (haplo-HSCT) from a pooled analysis of two Phase II trials (CR-AIR-007, NCT01794299; CR-AIR-008, NCT02500550) at the 59th Annual Meeting of the American Society of Hematology (ASH).
  • 28 Jun 2019 According to a Kiadis Pharma media release, the European Medicines Agency informed Kiadis that it will convene a Scientific Advisory Group (SAG) in September to assist EMA in arriving at a determination. With the SAG meeting now preceding the subsequent CAT and CHMP meetings as part of the EMA approval process, the company is changing its guidance to potential EU conditional approval in 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top